ChemoCentryx (CCXI) Received its Third Buy in a Row

After Piper Sandler and Leerink Partners gave ChemoCentryx (NASDAQ: CCXI) a Buy rating last month, the company received another Buy, this time from H.C. Wainwright. Analyst Edward White reiterated a Buy rating on ChemoCentryx today and set a price target of $69.00. The company’s shares closed last Monday at $55.50, close to its 52-week high of $59.20.

According to, White is a top 100 analyst with an average return of 28.5% and a 54.7% success rate. White covers the Healthcare sector, focusing on stocks such as Spectrum Pharmaceuticals, Karyopharm Therapeutics, and TRACON Pharmaceuticals.

Currently, the analyst consensus on ChemoCentryx is a Strong Buy with an average price target of $70.33, implying a 42.7% upside from current levels. In a report issued on May 11, Piper Sandler also maintained a Buy rating on the stock with a $54.00 price target.

See today’s analyst top recommended stocks >>

Based on ChemoCentryx’s latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $5.86 million and GAAP net loss of $21.69 million. In comparison, last year the company earned revenue of $8.33 million and had a GAAP net loss of $11.95 million.

Based on the recent corporate insider activity of 47 insiders, corporate insider sentiment is neutral on the stock.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

ChemoCentryx, Inc. is a biopharmaceutical company engages in the development and commercialization of medicines. It focuses on inflammatory disorders, autoimmune diseases, and cancer. Its drug candidates such as Avacopan and CCX140, selectively blocks a specific chemoattractant receptor, leaving the rest of the immune system intact. The company was founded by Thomas J. Schall in 1997 and is headquartered in Mountain View, CA.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts